Navigation Links
Scripps Research wins more than $2 million to study prostate cancer

JUPITER, FL, April 26, 2011 The Scripps Research Institute and Tampa's Moffitt Cancer Center have been awarded more than $2 million to study the formation and progression of prostate cancer. Of the funds awarded, approximately $1.9 million will go to Scripps Research, with the remaining $138,380 supporting Moffitt Cancer Center work.

The five-year grant from the National Institutes of Health (NIH) will fund research to advance the development of novel therapeutic strategies for prostate cancer treatment and prevention.

"This new funding will help us continue our work into the origins of prostate cancer and the role that inflammation plays in its development," said Jun-Li Luo, PhD, an assistant professor on the Florida campus of Scripps Research and principal investigator for the new study. "We are pleased that Moffitt, one of the country's leading treatment and research centers, will be our partner in this research. Gaining a better understanding of the inflammatory process should help lay the foundation for developing novel therapeutic strategies for this disease."

"This collaboration with Scripps Florida is a great opportunity to help uncover the underlying mechanisms of prostate cancer," said Shohreh Dickinson, MD, an assistant professor at Moffitt, where scientists will study and interpret pathology slides of human cells as part of the new study. "It's also a great opportunity for two Florida research centers to advance the science that, hopefully, will one day help put an end to this terrible disease."

Prostate cancerwhich, according to the American Cancer Society, will affect one in six American men in their lifetimeis the second-leading cause of death after lung cancer in American men. Prostate cancer is driven by androgen, the male sex hormone, and androgen deprivation is considered a first-line treatment of the disease once it spreads beyond the prostate gland.

Eventually, all prostate cancer becomes resistant to the treatment, and the disease grows independently of androgen. This can occur almost anytime during treatment. Currently there are no effective treatments for what is known as hormone-refractory prostate cancer.

Luo's work has long been focused on the role of inflammation in cancer and the body's innate inflammatory response, which encourages tumor growth. In earlier studies, he found that blocking one of the factors involved in inflammationthe nuclear factor-kappa B (NF-kB)dramatically impaired development of the disease. In addition, Luo has identified tumor-infiltrating B cells as another critical component of the inflammatory response that enhances androgen-independent tumor growth.

The new study will further define how B cells control the spread of hormone refractory cancer.


Contact: Mika Ono
Scripps Research Institute

Related medicine news :

1. New lupus drug results from Scripps Research technology
2. Scripps Research and MIT scientists discover class of potent anti-cancer compounds
3. Scripps Research study points to liver, not brain, as origin of Alzheimers plaques
4. Scripps Research compound blocks brain cell destruction in Parkinsons disease
5. Scripps Research scientists develop powerful new methodology for stabilizing proteins
6. Scripps Research scientists find measles natural nemesis
7. Scripps Research scientists awarded $2.35 million to study new obesity treatment
8. Scripps Research scientists identify first synthetic activator of 2 critical proteins
9. Scripps Clinic nurse to receive 2010 ASTRO Nurse Excellence Award
10. Scripps and Trius team up to develop new antibiotics with US Department of Defense grant
11. Scripps Research scientists solve long-standing mystery of protein quality control mechanism
Post Your Comments:
(Date:11/30/2015)... Ill. (PRWEB) , ... November 30, 2015 , ... ... Decision Support Solutions, announced at the Radiology Society of North America (RSNA) annual ... have seen over 60% growth from 2014. Throughout 2015, the company has ...
(Date:11/30/2015)... ... November 30, 2015 , ... Since its inception, Seniors Guide ... living, assisted living and all other retirement options. Support for issues surrounding the ... remains a top priority. , So it’s no surprise that every November, ...
(Date:11/30/2015)... Washington, DC (PRWEB) , ... ... ... Services, Inc. (AIS) is pleased to announce the speakers for “Value-Based Payer-Provider ... valuable lessons learned from three innovative value-based care arrangements: Essentia Health and ...
(Date:11/30/2015)... PA (PRWEB) , ... November 30, 2015 , ... ... software provider, has verified that their Vasont Universal Integrator (VUI) extension unites with ... creating, editing, and managing content as a continuous process with the latest release ...
(Date:11/30/2015)... ... 30, 2015 , ... Scott Newman MD, FACS of New ... plastic surgeons in the New York City area to utilize the new, non-invasive ... heat-induced laser treatment for fat loss in the abdomen, flanks, and other areas ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... Nov. 30, 2015 (HK$,000)For the Six Months Ended 30 September 2015 2014RestatedChange%Turnover ... , 421,979 , 384,242 , ... , 34,719 , (18.3) Medical Insurance Administration ... , 16.1 Medical Devices and Accessories Sales , ... Chinese Herbal Medicines Sales , 2,822 , 2,917 ...
(Date:11/30/2015)... INDIANAPOLIS , Nov. 30, 2015  PTS Diagnostics, ... as CardioChek ® analyzers, A1CNow ® systems, ... of a family of patents that will propel the ... and Europe . The ... cameras, such as those on smartphones and tablets, and ...
(Date:11/30/2015)... , Nov. 30, 2015 Cumberland Pharmaceuticals (CPIX), today ... live at on December 3, 2015. TIME: ... TIME: 3:15p.m. ET LINK: --> ... --> ... where investors are invited to ask the company questions in ...
Breaking Medicine Technology: